Lunch and Learn | Faster to Phase II: High Speed, High Quality & Non-Dilutive Funding for Biopharmaceutical Programs

BayBio Events
In this event you will hear from financial, manufacturing, bioanalytical, clinical & regulatory experts on how Australian initiatives are enabling U.S. based companies to progress their biopharmaceutical programs to Phase II faster and cheaper than anywhere else in the world, whilst maintaining the high quality standards required by global regulatory authorities. Our special guest, Tunitas Therapeutics, will speak about their experience with these initiatives and the significant value they have brought to their San-Francisco based biotech company.

  • Non-dilutive financing for biopharmaceutical programs part run in Australia – up to 45% cash refund provided by the Australian Tax Office through the R&D Tax Incentive.
  • Clinical trial start in as little as 4 weeks using the Australian Clinical Trial Notification scheme allowing fast track progression to global Phase II trials.

Speakers

 

What:

Lunch and Learn | Faster to Phase II: High Speed, High Quality & Non-Dilutive Funding for Biopharmaceutical Programs

When:

November 20, 2014
11:00AM – 1:00PM

Where:

HCP/BayBio Event Center
250 E. Grand Avenue, Suite 26
South San Francisco, CA 94080

Cost:

Members: Complimentary
Non-Members: $75

Who should join this event? Virtual, small & entrepreneurial biotech companies, early stage biopharmaceutical developers, CMC & clinical consultants & biopharmaceutical investors. Any company considering outsourcing mammalian cell culture-based production, bioanalytical & clinical development programs.

In Collaboration with:

Patheon

BPA